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Ventricular tachycardias (VTs) can usually be treated by endocardial catheter ablation. However, some
VTs can arise from the epicardial surface, and their substrate can be altered only by epicardial catheter
ablation. There are two approaches to epicardial catheter ablation: transvenous and transthoracic.
The transvenous approach through the coronary venous system (CVS) has been commonly used because
it is easily accessible. However, this approach may be limited by the distribution of the CVS and
insufﬁcient radiofrequency energy delivery. Transthoracic epicardial catheter ablation has been devel-
oped to overcome these limitations of the transvenous approach. It is a useful supplemental or even
preferred strategy to eliminate epicardial VTs in the electrophysiology laboratory. This technique has
been applied for scar-related VTs secondary to often non-ischemic cardiomyopathy and sometimes
ischemic cardiomyopathy, and idiopathic VTs as the epicardial substrates of these VTs have become
increasingly recognized. When endocardial ablation and epicardial ablation through the CVS are
unsuccessful, transthoracic epicardial ablation should be the next option. Intrapericardial access is
usually obtained through a subxiphoidal pericardial puncture. This approach might not be possible in
patients with pericardial adhesions caused by prior cardiac surgery or pericarditis. In such cases, a hybrid
procedure involving surgical access with a subxiphoid pericardial window and a limited anterior or
lateral thoracotomy might be a feasible and safe method of performing an epicardial catheter ablation in
the electrophysiology laboratory. Potential complications associated with this technique include
bleeding and collateral damage to the coronary arteries and phrenic nerve. Although the risk of these
complications is low, electrophysiologists who attempt epicardial catheter ablation should know the
complications associated with this technique, how to minimize their occurrence, and how to rapidly
recognize and treat the complications that they encounter. This review discusses the indications,
techniques, and complications of the transvenous and transthoracic epicardial catheter ablation of VTs.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Catheter ablation is an effective treatment that can cure
ventricular tachycardias (VTs). VTs secondary to structural heart
diseases are usually ﬁrst treated by antiarrhythmic drugs and
implantable cardioverter-deﬁbrillators. When patients cannot tol-
erate antiarrhythmic drugs or antiarrhythmic drugs cannot control
VTs, resulting in multiple shocks from the deﬁbrillator, catheter
ablation of the VTs should be considered [1]. On the other hand,
catheter ablation may currently be a ﬁrst line treatment for
idiopathic VTs because of its high success rate and low risk of
complications [2].
VTs can usually be treated by endocardial catheter ablation.
However, some VTs can arise from the epicardial surface, and their
substrate can be altered only by epicardial catheter ablation [2,3].
There are two approaches in epicardial catheter ablation: transve-
nous and transthoracic [2,3]. The transvenous approach through
the coronary venous system (CVS) has been commonly used
because it is easily accessible. However, this approach may be
limited by the distribution of the CVS and insufﬁcient radio-
frequency energy delivery. Pioneering work on transthoracic
epicardial catheter ablation to treat VT via a transpericardial
approach was ﬁrst reported by Sosa and his colleagues in 1996
[4]. Since then, epicardial substrates of VTs have been increasingly
recognized and transthoracic epicardial mapping and catheter
ablation have been proven to enhance the success rate of catheter
ablation of VTs and to help the patients avoid a surgical procedure
[4–6]. This review discusses how to recognize, map and ablate
epicardial VTs and how to prevent, recognize, and manage the
complications associated with epicardial VT ablation.
2. How to recognize epicardial VT?
Electrophysiologists should make a decision regarding the
indications for epicardial mapping and ablation, based on the
electrocardiographic and electrophysiological ﬁndings during any
phase of the procedure.
2.1. Electrocardiographic recognition of epicardial VT
Twelve-lead electrocardiogram (ECG) tracings are very helpful
for determining the likely epicardial VT origin prior to the
electrophysiological study. In human hearts, the Purkinje network
is located only in the subendocardium. Because of this anatomical
background, ventricular activation from an epicardial origin
requires more time to reach the Purkinje network, resulting in a
slow onset of the QRS during epicardial VTs. Based on this
mechanism, several parameters predicting epicardial VT origins
have been proposed: a “pseudo-delta” wave duration 434 ms,
QRS complex duration 4200 ms, delayed intrinsicoid deﬂection
of 485 ms, RS complex duration 4121 ms, and maximum
deﬂection index (MDI) (calculated by dividing the shortest time
from the QRS onset to the maximum deﬂection in any of the
precordial leads by the total QRS duration) 40.54 [7,8]. When the
ventricular activation propagates from the epicardial origin in
the left ventricular free wall or ventricular posterior wall, the total
activation vector should go from lateral toward medial, or from
inferior toward superior, resulting in a QS pattern in lead I or aVF.
On the other hand, when the ventricular activation propagates
from an endocardial origin on the left ventricular free wall or
ventricular posterior wall, a part of the activation vector should go
toward the lateral or inferior direction, which reﬂects the activa-
tion conducting through the wall of ventricular muscle toward the
epicardium, resulting in the presence of an initial R wave in lead I
or aVF. Therefore, a QS pattern in lead I or aVF suggests an
epicardial origin in the left ventricular free wall [9] or the
ventricular posterior wall, respectively (Fig. 1).
2.2. Electrophysiological ﬁndings
Endocardial mapping, as well as transvenous epicardial map-
ping within the CVS, may provide useful electrophysiological
ﬁndings suggesting epicardial VT origins before a decision is made
to proceed with a transthoracic pericardial approach. These are
discussed in the next section.
3. How to map epicardial VT?
3.1. Endocardial and transvenous epicardial mapping
During the electrophysiological study, a multipolar mapping
catheter placed in the coronary sinus (CS) is very helpful for
predicting an epicardial origin of VTs. If the tachycardia is thought
Fig. 1. Schema showing the mechanism to explain the difference in the QRS
morphology in lead aVF during ventricular tachycardias with endocardial (left) and
epicardial (right) foci. Inf.¼ inferior; L¼ left; R¼right; and Sup.¼superior.
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to originate from the superior aspect of the ventricle, the CS
catheter is placed as distally as possible, usually at the junction of
the great cardiac and anterior interventricular veins (Fig. 2).
A micro-mapping catheter or guide wire can be used to map
within small cardiac veins [10,11]. During activation mapping of
VTs, an intracardiac electrogram with a presystolic ventricular
activation recorded from the CS catheter suggests an epicardial VT
origin. However, for further conﬁrmation, activation mapping
should be added to this vein and the surrounding epicardial
surface, aortic sinus cusps, and adjacent endocardial left ventricle
(LV). For focal VTs, local ventricular activation at suitable ablation
sites always precedes the QRS onset (usually by 420–30 ms),
while for reentrant VTs, mid-diastolic potentials are usually
recorded at the proposed ablation sites. When endocardial and
transvenous epicardial activation mapping does not identify such
proposed ablation sites, transthoracic epicardial mapping should
be considered next. When endocardial activation mapping identi-
ﬁes a far-ﬁeld electrogram with an early ventricular activation, an
epicardial VT origin may be suggested (Fig. 3) [12].
When activation mapping during VTs is not available because
of a hemodynamic collapse or infrequency or non-inducibility of
VTs, substrate mapping and pace mapping should be an alter-
native. Substrate mapping is performed to seek a scar with late
and isolated diastolic potentials that are associated with a sub-
strate for scar-related reentrant VTs. When endocardial substrate
mapping does not identify any scars with such late and isolated
diastolic potentials, transthoracic epicardial mapping should be
considered next. Pace mapping can be used to identify the site of a
focal VT origin and the exit site of a reentrant VT. Pace mapping
may also be helpful for roughly localizing the site of the VT origin.
A comparison of pace maps from the endocardial sites and those
from the epicardial sites such as the CVS or VTs, could help to
predict whether the VT origin can be ablated from the endocardial
or epicardial surface. If the MDI during VTs is clearly greater than
that during endocardial pace mapping, or the MDI during pace
mapping from the CVS is more similar to that during VTs than to
that during endocardial pace mapping, transthoracic epicardial
mapping should be considered.
3.2. Transthoracic epicardial mapping
When a suitable ablation site is identiﬁed within the CVS,
epicardial ablation within the CVS should be attempted before
proceeding with the transthoracic pericardial approach. Transthor-
acic epicardial mapping should be considered when endocardial
mapping or epicardial mapping through the CVS fails to identify a
presumable target site for ablation that meets the criteria for a
successful ablation, or when endocardial and epicardial ablation
through the CVS is unsuccessful [5,8,13–15].
Intrapericardial access is obtained through a subxiphoidal
pericardial puncture, with an 18-gauge epidural introducer needle
at an angle of 20–301 advanced into the pericardial space, aiming
toward the left mid-clavicle at the cardiac border under ﬂuoro-
scopic guidance (Fig. 4) [1]. The angle of this entry may be
adjusted according to whether an anterior or posterior approach
is preferred. Puncturing below the cartilage of the ribs usually
does not encounter strong resistance until the stronger resistance
of the diaphragm is felt. The cardiac contraction can be felt
through the needle itself. Crossing this relatively thin zone, which
is directly attached to the strong texture of the ﬁbrous pericar-
dium, should be performed under constant negative pressure.
When the pericardial space is entered, a small volume (2–3 mL) of
pericardial ﬂuid can be aspirated. Subsequently, contrast medium
is injected to demonstrate the position of the needle tip, and a
J-tipped, ﬂoppy guidewire is then introduced through the needle
until its tip is free within the pericardial space. A long sheath is
advanced into the pericardial space over the guidewire to enable
Fig. 2. Computed tomographic (CT) (left panels) and ﬂuoroscopic (right panels) images showing the summit of the left ventricle (LV). The LV summit was deﬁned as the
region on the LV epicardial surface near the bifurcation of the left main coronary artery (LMCA) that is bounded by an arc (black dotted line) from the left anterior descending
coronary artery (LAD) superior to the ﬁrst septal perforating branch (black arrowheads) extending anteriorly to the left circumﬂex coronary artery (LCx) laterally. The great
cardiac vein (GCV) bisects the LV summit into a superior portion, surrounded by the white dotted line (the inaccessible area), and an inferior portion, surrounded by the red
dotted line (the accessible area). The white arrowheads indicate the ﬁrst diagonal branch of the LAD. The ablation catheter (ABL) was positioned at the successful ablation site
in the accessible area. AIVV¼anterior inter-ventricular cardiac vein; Ao¼aorta; and PA¼pulmonary artery.
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Fig. 4. CT image (left upper panel) exhibiting the anterior (red arrow) and posterior (green arrow) pericardial approaches, and ﬂuoroscopic images exhibiting the pericardial
puncture (right upper panels, A; tenting on the diaphragm, B; puncture through the diaphragm, C; tenting on the pericardium, D; contrast injected into the pericardial space)
and guidewires (arrowheads) correctly positioned in the pericardial space (left and middle lower panels) and inadvertently introduced into the right ventricular outﬂow
tract (right lower panel). AP¼antero-posterior; CS¼coronary sinus; HB¼His bundle; RV¼right ventricle.
Fig. 3. Endocardial and epicardial activation maps during the epicardial ventricular tachycardia (VT) (right panels) with cardiac tracings recorded from the endocardial and
epicardial earliest ventricular activation sites in those maps (left panels). (A) Epicardial ventricular activation before the ablation. (B) Endocardial ventricular activation before
the ablation. (C) Endocardial ventricular activation after the ablation. The single arrowheads indicate the near-ﬁeld electrograms and the double arrowheads the far-ﬁeld
electrograms. Note that radiofrequency ablation at the endocardial earliest ventricular activation site attenuated and delayed the second component of the double potential.
ABL¼ablation catheter; CS¼coronary sinus; Endo¼endocardium; Epi¼epicardium; LV¼ left ventricle; RV¼right ventricle; Xd,p¼the distal and proximal electrode pairs of
the relevant catheter.
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aspiration of pericardial ﬂuid and delivery of the ablation catheter
to the epicardial surface of the atrium and ventricle.
The percutaneous subxiphoidal intrapericardial approach
might not be possible in patients with pericardial adhesions
caused by prior cardiac surgery or pericarditis. Because pericardial
adhesions are anticipated to be denser in the anterior wall, the
non-surgical transthoracic epicardial puncture may have to be
directed to the inferior wall of the LV, allowing for ablation of the
inferolateral LV [16]. Accumulation of contrast medium in the
inferior wall, rather than spreading around the cardiac silhouette,
during the epicardial puncture procedure may suggest pericardial
adhesions (Fig. 5). The catheter can be used to gently lyse
adhesions manually, by vibration, or by applications of radio-
frequency energy. In individuals with pericardial adhesions, a
hybrid procedure involving surgical access with a subxiphoid
pericardial window and limited anterior or lateral thoracotomy
might be a feasible and safe method of performing an epicardial
catheter ablation in the electrophysiology laboratory (Fig. 5) [17].
Once the mapping catheter is introduced through the sheath
into the pericardial space, the catheter can usually move around
without difﬁculty. However, a deﬂectable sheath may sometimes
be required to facilitate better access and contact of the ablation
catheter at the presumable target region.
4. How to ablate epicardial VT?
An irrigated radiofrequency ablation catheter is used for
epicardial sites accessed via the transvenous or transthoracic
pericardial approaches. Irrigation enables radiofrequency energy
to be delivered to locations where little or no convective cooling of
the ablation electrode by blood ﬂow occurs. Irrigated radiofre-
quency ablation is more effective than non-irrigated radiofre-
quency energy for generating epicardial lesions in the presence
of epicardial fat interposed between the ablation electrode and the
target site in the myocardium [18]. The ablation electrode can be
irrigated either internally or externally. Irrigated radiofrequency
ablation is delivered for 1–2 min at each ablation site with the
electrode in power-control mode, starting at 20 W in the CVS,
including the great cardiac vein, anterior interventricular vein and
middle cardiac vein, and 30 W on the epicardial surface, with an
irrigation ﬂow rate of 30 mL/min [19,20]. If the initial radio-
frequency power is not effective, it is increased to a maximum of
30 W in the CVS, and 50 W on the epicardial surface; care is taken
to limit the electrode temperature to o41 1C [20]. During this
treatment, a decrease in the impedance of 5–10 Ω represents the
formation of good radiofrequency lesions.
The efﬁcacy of transvenous and transthoracic epicardial radio-
frequency ablation might be limited by its inaccessibility to the
myocardial site of origin, close proximity to the coronary artery, or
an epicardial location that lies beneath a fat pad (i.e., near the
atrioventricular groove). Cryothermal ablation might be a viable
alternative to radiofrequency ablation in patients with a high
impedance over a thick fat pad, or a VT origin close to a coronary
artery, because it is not limited by impedance and is safer than
radiofrequency ablation, posing a lower risk of damage to the
vessel and thrombus formation [13]. An absence of circulating
blood in the pericardial space may favor the creation of cryo-
lesions on the epicardium.
5. Speciﬁc concerns of each VT substrate
5.1. Idiopathic VT
Some of the major sites of idiopathic VT origins are epicardial,
including the LV summit [15] and crux of the heart [14]. A region of
the LV epicardial surface bounded by the left anterior descending
and circumﬂex coronary arteries that lies superior to the aortic
portion of the LV ostium occupies the most superior portion of the
LV and has been termed the LV summit (Fig. 2) [15]. The great
cardiac vein divides this region between an inferior area accessible
Fig. 5. Fluoroscopic images showing accumulation of the contrast medium in the inferior wall in a repeated epicardial procedure, suggesting a pericardial adhesion
(left panels), and a photograph of a hybrid procedure involving surgical access with a limited lateral thoracotomy. Right coronary artery¼RCA.
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to ablation and a superior, inaccessible area. VTs arising from the
LV summit can most often be ablated within the great cardiac vein.
Transthoracic epicardial ablation is usually successful in the
accessible area, whereas it is usually unsuccessful in the inacces-
sible area because of the close proximity to the coronary arteries
or a high impedance (Fig. 2) [15]. The crux of the heart is formed
by the junction of the atrioventricular groove and posterior
interventricular groove and corresponds roughly to the junction
of the middle cardiac vein and CS, near the origin of the posterior
descending coronary artery (Fig. 6) [14]. When transvenous
epicardial ablation is unsuccessful, transthoracic epicardial abla-
tion should be considered. The activation time and pace map in
the cardiac veins are helpful as a reference during transpericardial
mapping. Catheter ablation in the LV summit and crux entails a
potential risk of damage to the coronary arteries. Therefore,
coronary angiography is mandatory to prevent this complication
during catheter ablation in these regions.
5.2. Scar-related VT
The mechanism of scar-related VTs is predominantly based on
macro reentry. A critical site of such a reentrant circuit as a
presumable ablation target is indicated by a mid-diastolic poten-
tial during monomorphic, hemodynamically stable VT [2,21], areas
of low voltage in the local ventricular electrograms and the sites
responsible for isolated diastolic potentials, and late potentials
identiﬁed by substrate mapping during sinus rhythm or constant
ventricular pacing [2,22–24]. When endocardial mapping fails to
identify the area of interest or endocardial ablation fails, trans-
thoracic epicardial mapping should be performed [5,25–28].
An epicardial VT substrate is common in patients with non-
ischemic cardiomyopathy (NICM) [25–27,29] or Chagas disease,
[4,6] but less likely (up to approximately 1/3) to be present in
patients with ischemic heart disease [5]. In patients with arrhyth-
mogenic right ventricular cardiomyopathy, an epicardial substrate
might be eliminated by endocardial ablation, since the wall of the
right ventricle (RV) is not thick. However, the necessity of
performing epicardial ablation is increasingly being recognized
in these patients [27,30]. In patients with NICM, it is not uncom-
mon for the endocardial bipolar voltage map to be normal. In such
a setting, unipolar endocardial voltage mapping might be able to
predict sites of epicardial scar (an area with a local endocardial
unipolar voltage of o5.5 mV in the RV and 8.3 mV in the LV seems
to correlate with epicardial scar) and thus localize the area of
interest for bipolar epicardial mapping (Fig. 7) [24,31,32]. In
ischemic VTs, epicardial reentry circuits, in general, are more
frequent in the inferior, as opposed to the anterior wall [16,18].
6. Complications
Potential complications associated with epicardial catheter
ablation of VTs are very rare and the procedures are generally
safe [4–6,11,13–16,17,25,33–35]. However, transthoracic epicardial
access and ablation could result in uncommon complications [36].
The electrophysiologists should be aware of the relevant compli-
cations, and know how to minimize their occurrence, and how to
rapidly recognize and treat the complications that they encounter.
Therefore, these procedures should be performed at well-
experienced heart rhythm centers.
6.1. Transvenous epicardial approach
In this approach, an ablation catheter is introduced and
manipulated in the CVS, and ablation energy is delivered within
the CVS. Therefore, there is a potential risk of damage to the vessel,
such as extravasation, perforation, stenosis or occlusion, as well as
thrombus formation within the vessel. If a smaller and softer
multipolar mapping catheter is placed within the CVS ﬁrst, it can
guide the introduction of the ablation catheter. During mapping
Fig. 7. Bipolar (left and middle panels) and unipolar (right panels) voltage maps of
the LV endocardium (ENDO) and epicardium (EPI) in a case with an aneurysm in
the LV lateral wall. In the bipolar voltage maps, the purple and red indicate the
areas where the amplitude of the local bipolar electrogram is Z1.5 mV (left panels)
or 4.0 mV (middle panels) and r0.5 mV, respectively. In the unipolar voltage
maps, the purple indicates the area where the amplitude of the local unipolar
electrogram is Z7.6 mV (¼30% of the maximal amplitude). The white arrowheads
indicate the aneurysm. BI¼bipolar; LL¼ left lateral; PA¼postero-anterior;
SUP¼superior; and UNI¼unipolar.
Fig. 6. Fluoroscopic images showing a successful ablation site at the crux of the heart.
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through the CVS, a venous phase of the coronary angiography
and CS venogram obtained by a contrast injection through
the irrigation lumen of the ablation catheter may be helpful for
delineating the CVS and guiding mapping and ablation within
the CVS (Fig. 8) [37]. To prevent these complications, radiofre-
quency ablation should not be performed within small branches
of the CVS—although a rise in the impedance and/or tip tempera-
ture may not allow for such an ablation. Cryothermal ablation
may be safer than radiofrequency ablation because of the lower
risk of damage to the vessel and thrombus formation [13].
In this approach, there is also a potential risk of collateral
damage to the coronary arteries, such as spasms, stenosis, occlu-
sions, or thrombus formation within the coronary arteries,
and also to the left phrenic nerve. Anatomically, the CVS usually
runs below the coronary arteries, but rarely over them. Ablation
should not be performed over the coronary arteries. When the
ablation is performed below the coronary arteries, it may be safe
because of fat with high impedance lying between the CVS and
coronary arteries, and a cooling effect from the blood ﬂow through
the coronary artery. However, prior coronary angiography is
strongly recommended to determine a safer area for the radio-
frequency ablation. It may be important to maintain a distance of
more than 5 mm between the coronary artery and the distal
electrode of the ablation catheter at every point of the cardiac
cycle, in order to reduce the risk of damage to the coronary artery
during the radiofrequency ablation.
Left phrenic nerve stimulation can often be encountered during
an LV lead placement through the CVS. Therefore, transvenous
epicardial ablation may cause left phrenic nerve injury. Prior to the
ablation in the areas of concern, pacing should be performed with
a high output of 20 mA at a pulse width of 2 ms to ensure the lack
of phrenic nerve capture.
6.2. Transthoracic pericardial approach
6.2.1. Complications related to the pericardial access
Most critical complications can occur during pericardial access.
During transthoracic epicardial access, [4–6,28] an inadvertent
puncture of a cardiac vessel or chamber may sometimes occur as a
“dry” puncture, with only a few milliliters of pericardial ﬂuid.
Careful preparation and detailed knowledge of the underlying
anatomy may be the key to prevention of these complications.
The subxiphoid approach involves blindly passing a needle from
the skin, through the subcutaneous fat, rectus muscle, and usually
the diaphragm. In patients with congestive heart failure, the left
lobe of an enlarged liver may also be punctured [36]. Arterial
vessels in any of these structures may be punctured. In order to
minimize these complications, systemic anticoagulation with
heparin should not be administered or must be reversed if already
administered before the epicardial access.
Inadvertent puncture of the RV is relatively common. However,
in patients who are not anticoagulated, RV perforations are usually
benign if only the needle or guidewire has entered the chamber.
Therefore, it is important to recognize the RV perforation before
introducing the pericardial sheath. RV perforations may be easily
recognized with a contrast injection. If the needle is within the RV,
it should be slightly retracted until contrast is seen surrounding
the heart within the pericardial space. At this point, an attempt to
feed the guidewire into the pericardial space may be made, rather
than withdrawing the needle completely and starting anew.
However, even with this precaution the guidewire may still be
introduced into the RV through the needle. The ﬁrst sign suggest-
ing this may be arrhythmias, and is usually a run of premature
ventricular contractions coming from the RV outﬂow tract while
the guidewire is advancing through it (Fig. 4). The second sign may
Fig. 8. Fluoroscopic images showing the great cardiac venograms during a contrast injection through an external irrigation catheter. In Case 1, the tip of the ablation catheter
was positioned in the main trunk of the GCV, whereas in Case 2 it was in a small branch of the GCV. In both cases, the contrast ﬁlled even the peripheral branches and clear
venograms were obtained. ABL¼the externally irrigated ablation catheter.
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be the lack of a typical appearance of the guidewire in the
pericardial space on the ﬂuoroscopic images as more guidewire
is advanced [38]. It is essential to observe the guidewire in the left
anterior oblique projection, and to ensure that it hugs the cardiac
silhouette, crosses more than one chamber, and is circumferential
to both the right and left heart (Fig. 4). Observation in the right
anterior oblique or antero-posterior projection alone can be
misleading.
With a transthoracic pericardial approach, approximately
10–30% of patients experience some degree of pericardial bleeding
that can be managed with percutaneous drainage from the
pericardial catheter. It is not uncommon to aspirate 10–30 mL of
bloody drainage from the pericardial catheter early in the proce-
dure. However, if a large amount of blood is present in the
pericardial space, it can be autotransfused through a venous
sheath. Generally, bleeding ceases within 5–10 min and is self-
limited. If hemostasis cannot be obtained in this way, surgical
repair should be considered without delay. If the sheath has been
introduced into the RV by mistake, a second attempt to obtain the
correct pericardial access should be made, leaving the ﬁrst sheath
in place. The sheath may be surgically removed after the epicardial
catheter ablation has been completed.
Infrequently (0.5% in one case series [28]), intra-abdominal
bleeding may occur during the pericardial puncture, resulting in a
hemoperitoneum that may require a blood transfusion and surgi-
cal hemostasis. Bleeding within the liver may occur when the
needle penetrates an enlarged liver, which covers the course of the
puncture needle in heart failure patients [36]. Abdominal pain and
Blumberg's sign may lead to the diagnosis of this complication.
Therefore, conscious sedation may be preferred so that this ﬁnding
may be detected early.
During positioning of the pericardial sheath and the introduc-
tion of a mapping catheter through the sheath, air may inadver-
tently be aspirated into the pericardial space (Fig. 9) [39].
Aspirated pericardial air may be easily recognized in the apex on
the ﬂuoroscopic images. The pericardial air may rarely cause
cardiac tamponade. However, that may elevate the deﬁbrillation
threshold for a transthoracic deﬁbrillator, especially because the
air is likely to stay in an apical site, which is most anteriorly
located in the supine position (Fig. 9) [39]. In VT ablation,
cardioversion is often required for rescue from VT or ventricular
ﬁbrillation. Therefore, during an epicardial catheterization via a
pericardial puncture, careful attention should be paid to prevent
entry of air into the pericardial space and any aspirated air should
be evacuated from the pericardial space.
6.3. Complications during mapping and ablation
6.3.1. Pericardial effusion
The use of an externally irrigated ablation catheter requires
attention to the amount of pericardial ﬂuid that is instilled within
the closed pericardial space, because a pericardial tamponade may
result in impaired hemodynamics. Therefore, the pericardial ﬂuid
should be continuously aspirated through the sheath [38]. Use of
lower external irrigation ﬂow rates, such as 1 mL/min during
mapping and 10–17 mL/min during ablation, may help to control
the ﬂuid accumulation in the pericardial space, where thrombus
formation does not pose a risk of embolization.
6.3.2. Damage to the epicardial vessels
Transpericardial mapping and ablation may damage the epi-
cardial vessels, coronary artery, or coronary venous system. Such
damage includes laceration of vessels [36], acute coronary artery
spasms [36], and coronary artery occlusions.
Susceptibility to coronary artery damage by radiofrequency
ablation is inversely proportional to the proximity of the ablating
electrode and the vessel size [13]. It may be important to maintain
a distance of more than 5 mm between the coronary artery and
distal electrode of the ablating catheter at every point of the
cardiac cycle, in order to reduce the risk of damage to the coronary
artery during the radiofrequency ablation. Prior coronary angio-
graphy must be performed to determine a safer area for the
radiofrequency ablation. Because the base and anterior and poster-
ior septal areas are considered more dangerous zones, coronary
angiography should be performed before and during radiofre-
quency ablation in these areas. Chronic damage can occur to
coronary arteries despite the absence of acute effects. When the
target ablation site is located adjacent to the coronary arteries,
cryothermal ablation may be an alternative.
Fig. 9. Twelve-lead electrocardiogram of the ventricular tachycardia that was ablated (left upper panel), ﬂuoroscopic image demonstrating air aspirated into the pericardial
space (arrowheads) (upper right panel), and cardiac tracings demonstrating the induction of ventricular ﬁbrillation by programmed ventricular stimulation and multiple
extrathoracic cardioversions (lower panels).
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6.3.3. Phrenic nerve injury
Injury to the left phrenic nerve and consequent diaphragmatic
paralysis is a well-recognized complication of transthoracic epi-
cardial ablation. Especially, one of the limitations of transthoracic
epicardial ablation for NICM VT is the potential proximity of the
left phrenic nerve to the VT substrate. Anatomically, the left
phrenic nerve runs in the vicinity of the left atrial appendage
crossing the mitral valve annulus down to the posterolateral LV
while its course along the basal border of the LV is variable. [40].
The phrenic nerve is vulnerable to cold as well as heat, and
cryothermal ablation seems unlikely to prevent this complication
[41].
Pacing maneuvers can assist in identifying the phrenic nerve's
course, as well as ensuring an apparent safe distance for ablation.
Prior to epicardial ablation in the dangerous areas described
above, pacing is usually performed with a high output of 20 mA
at a pulse width of 2 ms to ensure lack of phrenic nerve capture. If
patients are paralyzed under general anesthesia, diaphragmatic
motion with phrenic nerve stimulation during pacing may not
occur to warn of the proximity. Therefore, conscious sedation may
be a better choice during epicardial ablation with an expected risk
of phrenic nerve injury.
When catheter ablation has to be performed adjacent to the left
phrenic nerve, left phrenic nerve injury may be avoided by
interposing a sheath, balloon [42], or even air [43] and saline
[44] in the pericardium between the ablation site and the nerve.
Air and/or saline should be gradually injected via a hemostatic
sheath into the pericardium until the loss of phrenic nerve
capture, with careful monitoring of the blood pressure to prevent
any iatrogenic cardiac tamponade. In the technique that uses a
balloon catheter in the pericardial space to mechanically separate
the left phrenic nerve from the ablation catheter, a steerable outer
sheath may be helpful for guiding the balloon placement and
providing additional support and stability.
6.3.4. Damage to the lungs
During transthoracic epicardial ablation, there is also a poten-
tial risk of collateral damage to the lungs surrounding the heart.
Although small pulmonary lesions can be anticipated, no clinical
signiﬁcance has been reported.
6.4. Postprocedural complications
6.4.1. Pericarditis
Symptomatic pericarditis is a common complication of epicar-
dial ablation. The clinical sign suggesting this complication may be
precordial distress and a pericardial friction rub. This complication
is usually mild, of a limited duration, and often responds well to
oral non-steroidal anti-inﬂammatory medications. However, the
intensity of the pericardial inﬂammatory reaction varies consider-
ably [45]. In general, the longer the procedure and the larger the
number of epicardial applications, the severer the epicardial
inﬂammatory reaction. In order to prevent pericarditis, several
measures may be recommended. First, all pericardial sheaths
should be removed at the end of the procedure unless there is
continued bleeding. Second, 0.5–1 mg/kg of methylprednisolone
or 2 mg/kg of an intermediate-acting corticosteroid (triamcino-
lone) should be injected intrapericardially. This treatment may
prevent any post-procedural inﬂammatory adhesion formation,
especially if a repeat procedure is necessary.
6.4.2. Pleuritis
Symptomatic pleuritis may occur after the procedure. The
clinical sign suggesting this complication may be dyspnea and a
pleural friction rub. This complication may be similar in its clinical
course to pericarditis and may respond well to oral non-steroidal
anti-inﬂammatory medications.
7. Conclusions
VTs can arise from the epicardial surface, and their substrate
can be altered only by epicardial catheter ablation with transve-
nous and transthoracic approaches. The transvenous approach
through the CVS is easily accessible, but may be limited by the
distribution of the CVS and insufﬁcient radiofrequency energy
delivery because of high impedance and temperature rise. Trans-
thoracic epicardial catheter ablation is a useful supplemental or
even preferable strategy to enhance the success rate of catheter
ablation of epicardial VTs. If potential complications associated
with this technique are well understood and managed, epicardial
catheter ablation of VTs can be performed safely.
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